Markets

Cidara Eliminates 30% Of Workforce To Prioritize Clinical Development Of CD388; Stock Down

September 12, 2024 — 11:51 pm EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Cidara Therapeutics Inc. (CDTX) has announced a reduction in its workforce by approximately 30% to concentrate on advancing the clinical development of CD388, the company's innovative DFC candidate targeting influenza A and B.

The strategic initiatives are expected to substantially reduce capital needs and allow Cidara to focus on its planned Phase 2b and potential subsequent trials investigating CD388 as a single-dose, universal preventative for influenza A and B.

The company continues business development discussions for its oncology drug-Fc conjugate (DFC) programs, including CBO421, a CD73 inhibitor, which recently received IND-clearance to commence a Phase 1 study.

CDTX closed Thursday's regular trading at $11.35 down $0.27 or 2.32%. In the after-hours trading, the stock further dropped $0.49 or 4.35%.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned

Latest Articles
Data is currently not available